Meta-analysis of 5 observational studies in type 2 diabetes: semaglutide was associated with higher NAION risk vs other glucose-lowering drugs (HR 2.17, 95% CI 1.73–2.74), but absolute risk was low (~1 extra case per 7,000 patients a year); certainty of evidence low.
Meta-analysisn = 5 studies
Chrzanowski et al. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies